Research records whose structured intervention field mentions HSCT or hematopoietic stem-cell transplantation. Review the source and study context for each entry.
This hub updates as matching research records are published. AI-generated summaries are labelled when they have not yet been reviewed by a person.
AI
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedHuman studyPhase 3Trial registry record – peer review not applicable
A phase 3 study involving 156 adults with relapsing MS is ongoing, comparing autologous hematopoietic stem cell transplantation to the best available therapy. The primary endpoint is MS relapse-free survival, with follow-up extending up to 72 months. However, no results from this study have been posted thus far.
What this does not proveThe study does not provide any results, limiting the ability to assess its effectiveness or safety at this time.
In a study of 30 people with multiple sclerosis undergoing AHSCT, reductions in paramagnetic rim lesion (PRL) count were observed. In a group followed pre and post-AHSCT, 40% of PRL-positive individuals showed decreased PRL counts, while 19% had resolved lesions. In the post-AHSCT group, 57% of PRL-positive cases showed decreases, with 50% resolution and no new lesions appearing.
What this does not proveThe study's limited size, absence of a control group, and being monocentric restrict the broader applicability of its findings. Additionally, causation cannot be established from this observational data.
An observational study is currently recruiting 15 patients with relapsing remitting multiple sclerosis to investigate the immune profiles in those treated with autologous haematopoietic stem cell transplantation compared to those receiving high efficacy disease modifying treatment over 24 months.
What this does not proveNo results are available yet, as the trial is still recruiting. The mechanisms of aHSCT in MS are not fully understood, and it remains unclear which patients might benefit from treatment.
In a study involving 24 patients with severe MS undergoing AHSCT, researchers found that the treatment decreased inflammatory cytokines and neuroinflammatory markers in serum and CSF over several years. They noted transient increases in certain cytokines post-treatment but these did not persist.
What this does not proveHowever, the research does not demonstrate the specific mechanisms by which AHSCT works, and biomarker differences suggest complex immune responses.
Research summaries are for information, not medical advice. Always consult your MS team before changing treatment.
Help us understand how PulseMS is used
With your permission, Google Analytics uses cookies to measure visits and interactions with research. It does not receive your email, account details or community posts. You can change your choice in the footer. Privacy details